Higher baseline LTF levels in ES-SCLC patients may predict durable chemoimmunotherapy outcomes, suggesting LTF as a potential biomarker for treatment response. LTF appears to suppress SCLC tumors by ...

ES-SCLC patients show limited benefit from 3L therapies, highlighting the need for novel treatments to improve outcomes. SCLC is aggressive, often diagnosed at an extensive stage, and treated with ...

Please provide your email address to receive an email when new articles are posted on . Small cell lung cancer (SCLC) remains a highly aggressive malignancy with limited treatment options in the ...

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope. Exciting new research presented at the American Society of Clinical Oncology (ASCO) 2025 conference is ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

SCLC patients tolerated the treatment well, with 13 to 30 percent of patients treated with the nivolumab or the combination regimens having high-grade toxicities. The most common toxicities associated ...

The global downturn in tobacco use has led to a significant decline in the number of patients who are diagnosed with small-cell lung cancer (SCLC) on a yearly basis. But for those who do have SCLC, ...